OakChart

Azora Therapeutics Inc

AZRHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

3.51-0.25 (-6.65%)
2026-11-12 00:32 CET
Market cap
9.87 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-57.80 USD m
Free cash flow, TTM
-11.13 USD m
EPS diluted, TTM
-16.54
P/E
-
Compare

Price

AZR against its 20, 50 and 200-day averages
2050200beatmiss
2.004.006.0010.4M20.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AZRclose 3.5120-day 3.9150-day 4.38200-day 3.153.5152w low

59.9% under the 52-week high of 8.75 on 12 Nov 2025. 52-week low 1.31 on 15 May 2026. Last 15 sessions, 70.5% high to low

Volume 0.21× normal · the line is the 50-bar volume average

Profile

AZR
52-week range, 30% of the way up
1.318.75

Azora Therapeutics, Inc. is a biopharmaceutical company that develops therapies for immune-mediated inflammatory diseases. Its investigational oral drug, AT177, is being develop for inflammatory bowel diseases, with an initial focus on ulcerative colitis. The company was founded by Julie Saiki and Matthew Davidson which is headquartered in Los Angeles, CA.

Employees6
IPOJul 27, 2018
Beta1.62
ATR, 14d0.58
Rel volume0.21
Short float9.12%
Inst own30.00%

Snapshot

6 groups

Valuation

Index-
Market Cap49.99M
Enterprise Value83.62M
Income-57.80M
Sales0.00M
Book/sh-14.61
Cash/sh2.02
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees6
IPOJul 27, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C1.74
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio5.63
Current Ratio5.63
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-16.54
EPS next Y-0.60
EPS next Q-0.30
EPS this Y59.23%
EPS next Y87.62%
EPS next 5Y58.58%
EPS past 3/5Y88.55% 53.46%
Sales past 3/5Y- -
EPS Y/Y TTM45.78%
Sales Y/Y TTM-
EPS Q/Q-144.05%
Sales Q/Q-
EarningsAug 17 BMO
EPS/Sales Surpr.-989.59% -

Ownership

Insider Own-
Insider Trans-
Inst Own30.00%
Inst Trans-
ROA-322.10%
ROE-265.94%
ROIC-241.16%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-10.31%
SMA50-19.82%
SMA20011.34%
Trades-

Technical

Shs Outstand2.63M
Shs Float2.38M
Short Float9.12%
Short Ratio4.15
Short Interest0.22M
52W High8.75 -59.89%
52W Low1.31 167.94%
Volatility9.20% 16.83%
ATR (14)0.58
RSI (14)43.32
Beta1.62
Rel Volume0.21
Avg Volume52.33K
Volume11,067

Performance

Perf Week-13.33%
Perf Month6.69%
Perf Quarter-20.05%
Perf Half Y154.35%
Perf YTD-36.18%
Perf Year-57.72%
Perf 3Y-93.50%
Perf 5Y-99.83%
Perf 10Y-
Recom1.00
Target Price10.75
Prev Close3.76
Price3.51
Change %-6.65%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Nov 02, 2026InitiatedTTD CowenBuy
Aug 03, 2026InitiatedAAlliance Global PartnersBuy$11+213.4%
Nov 14, 2024InitiatedRRodman & RenshawBuy$8+127.9%
Oct 30, 2018InitiatedMMaxim GroupBuy$5+42.5%
Oct 11, 2018InitiatedDDawson JamesBuy

Peers

Mkt cap
TickerCompanyMkt cap
CMNDClearmind Medicine Inc2.51M
QUITAchieve Life Sciences Inc663.73M
MNOVMedicinova Inc69.40M
ENSCEnsysce Biosciences Inc7.00M
ENVBEnveric Biosciences Inc6.67M
VTGNVistagen Therapeutics Inc8.34M
KTTAPasithea Therapeutics Corp17.77M
SILOSILO Pharma Inc2.92M
JUNSJupiter Neurosciences Inc2.82M
RLMDRelmada Therapeutics Inc472.55M

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Coastlands Capital LP10% OwnerJul 14 '26Buy2.652,0005,300387,075Jul 16 05:08 PM
Coastlands Capital LP10% OwnerJul 16 '26Buy2.751,2333,391388,308Jul 16 05:08 PM
Coastlands Capital LP10% OwnerJul 09 '26Buy2.7910,05328,048383,375Jul 13 10:30 AM
Coastlands Capital LP10% OwnerJul 10 '26Buy2.701,7004,590385,075Jul 13 10:30 AM
Coastlands Capital LP10% OwnerJun 29 '26Buy2.6025,00065,000373,322Jul 01 10:30 AM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 100
  • Azora Therapeutics Appoints Board of Directors with Extensive Drug Development and Inflammatory Bowel Disease Expertise (GlobeNewswire) -8.40%
  • Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis (GlobeNewswire) +36.12%
  • Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer (GlobeNewswire) -6.12%
  • Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis (GlobeNewswire) +11.15%
  • Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.78%
  • Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update (GlobeNewswire) +25.38%
  • Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing (GlobeNewswire) -10.88%
  • ADIL Stock Eyes Best Day In Over 5 Years Major Pipeline Overhaul And $64M Raise Fuel Rally (Stocktwits) +37.96%
  • Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing (GlobeNewswire)
  • Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update (GlobeNewswire)
  • Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 (GlobeNewswire)
  • Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program (GlobeNewswire)
  • Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-17-11.250-1.033-11.2500.000.004
2026Q12026-05-11-1.480-2.730-1.4760.000.001
2025Q42026-03-06-1.810-2.130-1.7970.000.003
2025Q32025-11-14-1.937-3.500-2.0230.000.003
2025Q22025-08-13-4.500-5.500-4.6090.00-1
2025Q12025-05-15-8.500-12.375-8.5200.000.002
2024Q42025-03-04-8.000-9.688-7.9960.000.004
2024Q32024-11-14-9.500-10.000-9.3900.000.003
2024Q22024-08-19-14.750-13.500-14.6930.000.003
2024Q12024-05-10-54.750-10.500-54.8140.000.002
2023Q42024-03-28-27.083-19.000-28.8610.000.002
2023Q32023-11-14-29.500-31.875-28.5890.000.002
2023Q22023-08-21-4.625-56.250-34.7880.000.001
2023Q12023-05-12-65.625-87.500-68.6310.000.001
2022Q42023-03-30-65.625-95.833-67.1380.000.003
2022Q32022-11-14-75.000-112.5-75.5440.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-1,525-1,588-1,5270.00-
2021FY-650-600-653.060.000.00
2022FY-318.75-350-7,9450.000.00
2023FY-90.000-114.63-135.970.000.00
2024FY-68.000-69.375-68.0070.000.00
2025FY-11.930-11.107-11.9300.000.00
2026FY--4.864--0.00
2027FY--0.602--0.00
2028FY--0.848--0.00
2029FY--1.143--0.00
2030FY--1.683--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-303000.000.000.00
2026Q3S2026-08-171000.000.000.00
2026Q3S2026-06-121000.000.000.00
2026Q3S2026-03-091000.000.000.00
2026Q3S2025-11-141000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00
2026Q3S2025-11-041000.000.000.00
2026Q3S2025-11-031000.000.000.00

Estimate history

EPS, annual-104.744-1527.431-545.006-546.263-653.063-7945.175-135.965-68.007-11.931-16.5441
Period201720182019202020212022202320242025TTM
EPS, quarterly-14.693-9.39-7.996-8.52-4.609-2.023-1.797-1.476-11.249
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0110.0110.0170.0230.0340.0020.0670.2591.1112.626
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.1720.2560.2590.2660.8610.9531.1111.5092.626
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.060.000.000.00
Gross Profit-0.00-0.00-0.00-0.00-0.00-0.06-0.00-0.00-0.00
Selling, General and Administrative Excl. Other11.497.808.286.8910.8617.6910.938.246.99
Research and Development2.012.623.231.271.958.405.853.970.37
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-11.49-7.80-8.28-6.89-10.86-17.74-10.93-8.24-6.99
Interest Expense-0.000.000.000.000.000.000.001.17
Unusual Expense43.960.000.000.00-0.521.830.000.443.48
Net Income Before Taxes-57.80-7.98-13.20-7.00-10.80-19.52-10.89-8.59-11.63
Income Taxes0.000.000.000.000.00-0.090.000.000.00
Consolidated Net Income-57.80-7.98-13.20-7.00-10.80-19.42-10.89-8.59-11.63
Net Income From Continuing Operations-57.80-7.98-13.20-7.00-10.80-19.42-10.89-8.59-11.63
Net Income-57.80-7.98-13.20-7.75-12.73-19.42-10.89-8.59-11.63
EPS (Recurring)-5.85-11.93-68.01-135.96-7,945.18-609.99-546.26-525.39-1,207.12
EPS (Basic, Before Extraordinaries)-16.54-11.93-68.01-135.96-7,945.18-653.06-546.26-545.01-1,527.43
EPS (Diluted)-16.54-11.93-68.01-135.96-7,945.18-653.06-546.26-545.01-1,527.43
EBITDA-11.49-7.80-8.28-6.89-10.86-17.69-10.93-8.24-6.99
Non-Operating Income (Expense)-2.35-0.18-4.91-0.110.060.050.030.100.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.600.680.801.753.373.102.131.605.37
Shares Outstanding2.631.110.260.070.000.030.020.020.01
Market Capitalization9.879.876.542.275.7756.5624.4724.9935.14

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Selling, General and Administrative Excl. Other5.842.001.891.761.882.271.942.21
Research and Development0.440.430.620.520.730.750.731.03
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.84-2.00-1.89-1.76-1.88-2.27-1.94-2.21
Interest Expense-0.000.000.000.000.000.000.00
Unusual Expense43.960.000.000.000.000.000.000.00
Net Income Before Taxes-51.99-2.02-2.00-1.79-1.96-2.23-2.07-2.19
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-51.99-2.02-2.00-1.79-1.96-2.23-2.07-2.19
Net Income From Continuing Operations-51.99-2.02-2.00-1.79-1.96-2.23-2.07-2.19
Net Income-51.99-2.02-2.00-1.79-1.96-2.23-2.07-2.19
EPS (Recurring)-4.59-1.48-1.80-2.02-4.61-8.52-8.00-9.39
EPS (Basic, Before Extraordinaries)-11.25-1.48-1.80-2.02-4.61-8.52-8.00-9.39
EPS (Diluted)-11.25-1.48-1.80-2.02-4.61-8.52-8.00-9.39
EBITDA-5.84-2.00-1.89-1.76-1.88-2.27-1.94-2.21
Non-Operating Income (Expense)-2.19-0.02-0.11-0.03-0.080.04-0.130.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.140.150.170.150.120.240.180.19
Shares Outstanding2.631.511.110.950.860.270.260.26
Market Capitalization9.872.566.118.436.514.226.546.40

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments5.883.752.834.006.064.406.783.870.02
Short Term Receivables0.040.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.260.310.370.780.400.730.900.820.01
Total Current Assets6.184.063.204.786.465.147.674.690.03
Net Property, Plant & Equipment0.000.000.000.240.300.000.000.000.00
Total Investments and Advances0.490.981.530.000.000.000.000.000.00
Long-Term Note Receivable----0.000.35---
Intangible Assets0.000.000.000.250.250.010.010.010.01
Deferred Tax Assets0.120.040.000.000.16----
Other Assets0.000.000.000.460.460.000.000.000.00
Total Assets6.805.084.745.737.635.497.684.700.03
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.060.050.000.000.000.69
Accounts Payable0.660.300.130.390.290.650.190.260.34
Other Current Liabilities0.740.680.531.342.390.860.350.000.00
Total Current Liabilities1.400.980.651.792.721.510.540.261.03
Long Term Debt0.000.000.000.000.210.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.120.040.000.000.18----
Other Liabilities0.000.000.000.671.010.000.000.000.00
Total Liabilities1.521.010.652.464.131.510.540.261.03
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity5.284.074.083.283.513.997.144.44-1.00
Total Shareholders Equity5.284.074.083.283.513.997.144.44-1.00
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity5.284.074.083.283.513.997.144.44-1.00
Total Liabilities & Stockholders Equity6.805.084.745.737.635.497.684.700.03
Book Value Per Share4.7515.7161.371,918.34104.66173.09430.43404.49-91.70
Tangible Book Value Per Share4.7515.6961.311,769.9597.09172.85430.06403.88-92.37
Full-Time Employees677201894--
Price to Book Ratio-0.261.610.971.0716.126.143.507.917.38
Return on Assets-134.29-268.81-131.91-161.53-295.97-165.41-138.81-491.42-1,224.75
Return on Equity-170.73-323.80-190.27-318.27-518.38-195.80-148.36-675.50-
Return on Invested Capital-151.18-324.41-189.74-388.57-522.81-273.28-120.32-261.89-
Quick Ratio4.424.164.902.672.373.4114.2418.190.03
Current Ratio4.424.164.902.672.373.4114.2418.190.03

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-57.80-7.98-13.20-7.00-10.80-19.42-10.89-8.59-11.63
Depreciation-0.000.000.000.000.060.000.000.00
Other Funds (Non Cash)47.111.025.890.990.786.052.012.049.98
Funds from Operations-10.70-6.96-7.31-6.01-10.01-13.41-8.88-6.55-1.65
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.440.470.39-0.79-1.171.461.250.21-0.85
Cash from Operating Activities-11.13-6.49-6.92-6.81-11.19-11.95-7.63-6.34-2.50
Capital Expenditures0.000.000.000.000.00-0.060.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.001.500.000.030.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00-0.350.000.00
Other Sources5.280.150.000.000.000.000.000.000.00
Cash from Investing Activities5.280.150.001.500.00-0.03-0.350.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock28.658.477.854.139.1313.645.619.256.42
Repurchase of Common Pref Stock0.000.000.00-0.000.000.000.000.000.00
Sale of Common Pref Stock28.658.477.854.139.1313.645.619.256.42
Proceedsfrom Stock Options26.063.664.020.759.1211.755.168.206.27
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00-0.07
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities28.658.477.854.139.1313.645.619.256.35
Net Change in Cash22.802.130.92-1.17-2.061.66-2.382.913.85
Free Cash Flow-11.13-6.49-6.92--11.19-12.01-7.63-6.34-2.50
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00-0.090.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments28.714.585.884.615.912.37
Short Term Receivables0.000.000.040.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.130.220.260.410.160.26
Total Current Assets28.844.806.185.016.082.63
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.240.420.490.640.720.82
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets--0.12---
Other Assets0.000.000.000.000.000.00
Total Assets29.095.236.805.666.803.45
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable2.620.570.660.560.670.53
Other Current Liabilities2.500.940.740.600.540.79
Total Current Liabilities5.121.511.401.151.211.32
Long Term Debt62.340.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.12---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities67.471.511.521.151.211.32
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-38.383.725.284.515.592.13
Total Shareholders Equity-38.383.725.284.515.592.13
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-38.383.725.284.515.592.13
Total Liabilities & Stockholders Equity29.095.236.805.666.803.45
Book Value Per Share-14.612.464.754.736.498.00
Tangible Book Value Per Share-14.622.464.754.726.497.98
Full-Time Employees--6---
Price to Book Ratio-0.260.381.161.871.161.98
Return on Assets-322.10-179.08-134.29-130.16-143.82-176.60
Return on Equity--265.94-170.73-155.01-171.27-217.01
Return on Invested Capital-216.91-54.41-37.83-39.81-35.03-104.80
Quick Ratio5.633.184.424.345.021.99
Current Ratio5.633.184.424.345.021.99

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-51.99-2.02-2.00-1.79-1.96-2.23
Depreciation-0.000.000.000.000.00
Other Funds (Non Cash)46.340.220.320.220.220.25
Funds from Operations-5.65-1.81-1.67-1.57-1.74-1.98
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.720.190.35-0.26-0.010.39
Cash from Operating Activities-6.36-1.61-1.32-1.83-1.75-1.59
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources5.280.000.000.000.000.15
Cash from Investing Activities5.280.000.000.000.000.15
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock25.210.322.600.525.300.05
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock25.210.322.600.525.300.05
Proceedsfrom Stock Options25.210.320.050.483.080.05
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities25.210.322.600.525.300.05
Net Change in Cash24.13-1.301.27-1.313.55-1.38
Free Cash Flow-6.36-1.61-1.32-1.83-1.75-1.59

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.12%0.2M2.4M58.91K
2026-10-157.54%0.2M2.4M57.05K
2026-09-307.70%0.2M2.4M58.15K
2026-09-158.82%0.2M2.4M72.98K
2026-08-3110.28%0.2M2.4M407.70K
2026-08-1410.34%0.2M2.2M451.73K
2026-07-3112.49%0.2M1.9M453.96K
2026-07-1513.03%0.2M1.9M471.04K
2026-06-3010.64%0.2M2.2M472.29K
2026-06-1516.37%0.3M2.1M456.26K
2026-05-292.24%0.0M2.1M155.44K
2026-05-152.42%0.1M2.1M113.44K
2026-04-304.86%0.1M1.4M110.65K
2026-04-153.48%0.0M1.4M95.96K
2026-03-316.97%0.1M1.4M83.38K
2026-03-135.73%0.1M1.4M71.75K
2026-02-272.58%0.0M1.1M30.09K
2026-02-133.12%0.0M1.1M24.43K
2026-01-301.01%0.0M1.1M13.50K
2026-01-151.07%0.0M1.1M15.45K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-103Initial statement of beneficial ownership of securities2026-11-03SEC
2026-11-103Initial statement of beneficial ownership of securities2026-11-03SEC
2026-11-103Initial statement of beneficial ownership of securities2026-11-03SEC
2026-11-098-KCurrent report2026-11-03SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-03SCHEDULE 13G/ASEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-28SEC
2026-10-303Initial statement of beneficial ownership of securities2026-10-28SEC
2026-10-303Initial statement of beneficial ownership of securities2026-10-28SEC
2026-10-288-KCurrent report2026-10-28SEC
2026-10-26EFFECTEffectiveness filing by commission orderSEC
2026-10-2110-Q/A2026-06-30SEC
2026-10-21S-3/ASEC
2026-10-16DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-168-KCurrent report2026-10-15SEC
2026-10-05DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-028-KCurrent report2026-10-01SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-18DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-188-KCurrent report2026-09-17SEC
2026-09-16DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-168-KCurrent report2026-09-16SEC
2026-08-28S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-28S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-258-KCurrent report2026-08-19SEC
2026-08-24ARSAnnual report to security holders. 2025-12-31SEC
2026-08-24DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-17SEC
2026-08-218-KCurrent report2026-08-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-0741.33K400
2026-0665.00K100
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
JANE STREET GROUP, LLC1.47%
CITADEL ADVISORS LLC1.35%
StoneX Group Inc.0.90%
GEODE CAPITAL MANAGEMENT, LLC0.82%
China Universal Asset Management Co., Ltd.0.49%
VANGUARD FIDUCIARY TRUST CO0.27%
VANGUARD CAPITAL MANAGEMENT LLC0.27%
Manchester Capital Management LLC0.07%
Tower Research Capital LLC0.06%
UBS Group AG0.06%

Funds

Fund% owned
-

OakChart. AZR. Cached 15 minutes.